Collapse all
The Business Model Canvas reveals a high-value, specialized diagnostic tool that shifts ADHD treatment from trial-and-error to precision medicine. The model relies heavily on strategic partnerships with pharmaceutical companies and clinical institutions to validate biomarkers and integrate the tool into standard psychiatric workflows.
4 Academic Research Institutions Partnerships with neuroscience labs to refine the specific dopaminergic signaling markers and validate clinical subgroups. Takeda Pharmaceuticals Collaboration for companion diagnostics to match specific ADHD subtypes with the most effective dopaminergic medications. Mayo Clinic Clinical partners to provide patient cohorts for validation studies and implement the tool in a high-volume medical setting. Diagnostic Lab Providers Partnerships with labs capable of processing the specific biomarkers required for the dopaminergic profiling. 4 Biomarker Validation Conducting rigorous clinical trials to correlate specific dopaminergic markers with patient response to treatment. Algorithm Development Building the diagnostic engine that categorizes patients into subtypes based on combined clinical and biological data. Regulatory Approval Navigating FDA or EMA pathways to certify the tool as a clinical diagnostic device. Clinician Training Educating child psychiatrists on how to interpret subtype data to adjust medication protocols. 3 Proprietary Diagnostic Framework The IP surrounding the specific dopaminergic profiles and the logic used to categorize ADHD subtypes. Patient Longitudinal Data Access to datasets tracking the relationship between dopamine markers and long-term treatment outcomes. Neuroscience Expertise Specialized talent in dopaminergic signaling and precision psychiatry to maintain the tool's scientific edge. 3 Reduced Trial-and-Error Eliminates the months of 'guess-and-check' medication cycles by predicting the most effective drug based on the patient's profile. Precision Stratification Provides child psychiatrists with a biological basis for diagnosis rather than relying solely on behavioral observations. Optimized Drug Efficacy Allows pharmaceutical companies to identify the exact patient population most likely to respond to their specific ADHD therapies. 2 B2B Clinical Integration Deep integration into the clinical workflow of psychiatric practices and hospitals via software licenses. Scientific Co-Development Collaborative relationships with research partners to continuously update the subtype markers as new evidence emerges. 3 Clinical Partnerships Direct deployment within major health systems like the Mayo Clinic. Medical Conferences Presenting validation data at psychiatry and neuroscience symposiums to drive adoption among specialists. Pharma Integration Bundling the diagnostic tool as a companion test for specific ADHD medications. 3 Child Psychiatrists Specialists seeking a more objective, biological method to guide ADHD medication choices for pediatric patients. Pharmaceutical Companies Companies like Takeda that need to stratify clinical trials and target the right patient subgroups for their drugs. Academic Medical Centers Institutions like the Mayo Clinic that prioritize precision medicine and cutting-edge diagnostic frameworks. 3 R&D and Clinical Trials High upfront costs for validating biomarkers and conducting longitudinal studies to prove efficacy. Regulatory Compliance Costs associated with obtaining FDA/EMA clearance for a medical diagnostic tool. Software Development Maintaining the secure, HIPAA-compliant platform used to process patient data and output subtype results. 3 Per-Test Licensing Fee A fee paid by clinics or insurance providers for every patient screened using the diagnostic tool. Pharma Partnership Royalties Revenue from pharmaceutical companies using the tool as a companion diagnostic for their ADHD drugs. Enterprise SaaS Subscription Annual licensing fees for large medical centers to integrate the diagnostic framework into their EHR systems. With named beneficiaries like Mayo Clinic and Takeda, the idea is concrete enough to map out the value proposition and revenue streams. · Generated 2026-10-02 by cavi/gemma4-31b-it-awq-4bit-32kAI-generated